FDA grants fast track designation to Innovent Biologics’ IBI343 in PDAC

Innovent Biologics, Inc. (HKEX: 01801), a prominent biopharmaceutical firm recognized for its innovative medicines, announced a pivotal advancement for its novel anti-CLDN18.2 ADC therapy, IBI343. ... Read More